A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Trebananib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-3
- Sponsors Amgen
- 07 May 2019 Primary endpoint (Progression free survival) has not been met, according to the results published in the Lancet Oncology.
- 07 May 2019 Results published in the Lancet Oncology
- 11 May 2017 This trial has been completed in Netherlands.